Evidence map›Paper›PMID 37386099›Full record

ArticleScientific reports2023

Feasibility of using intermittent active monitoring of vital signs by smartphone users to predict SARS-CoV-2 PCR positivity.

Nikola Dolezalova, Effrossyni Gkrania-Klotsas, Davide Morelli, Alex Moore, Adam C Cunningham, Adam Booth, David Plans, Angus B Reed, Mert Aral, Kirsten L Rennie and 1 more

Abstract read
In one paragraph

Article in Scientific reports, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Nikola DolezalovaHuma Therapeutics Ltd., Millbank Tower, 21-24 Millbank, London, UK.
Effrossyni Gkrania-KlotsasMRC Epidemiology Unit, Institute of Metabolic Science, University of Cambridge, Cambridge, UK.
Davide MorelliHuma Therapeutics Ltd., Millbank Tower, 21-24 Millbank, London, UK.
Alex MooreHuma Therapeutics Ltd., Millbank Tower, 21-24 Millbank, London, UK. alex.moore@huma.com.
Adam C CunninghamHuma Therapeutics Ltd., Millbank Tower, 21-24 Millbank, London, UK.
Adam BoothHuma Therapeutics Ltd., Millbank Tower, 21-24 Millbank, London, UK.
David PlansHuma Therapeutics Ltd., Millbank Tower, 21-24 Millbank, London, UK.
Angus B ReedHuma Therapeutics Ltd., Millbank Tower, 21-24 Millbank, London, UK.
Mert AralHuma Therapeutics Ltd., Millbank Tower, 21-24 Millbank, London, UK.
Kirsten L Rennie *MRC Epidemiology Unit, Institute of Metabolic Science, University of Cambridge, Cambridge, UK.
Nicholas J Wareham *MRC Epidemiology Unit, Institute of Metabolic Science, University of Cambridge, Cambridge, UK.

Funding

Department of Health IS-BRC-1215-20014Medical Research Council MC_UU_00006/1
6 · The paper itself

Abstract

Early detection of highly infectious respiratory diseases, such as COVID-19, can help curb their transmission. Consequently, there is demand for easy-to-use population-based screening tools, such as mobile health applications. Here, we describe a proof-of-concept development of a machine learning classifier for the prediction of a symptomatic respiratory disease, such as COVID-19, using smartphone-collected vital sign measurements. The Fenland App study followed 2199 UK participants that provided measurements of blood oxygen saturation, body temperature, and resting heart rate. Total of 77 positive and 6339 negative SARS-CoV-2 PCR tests were recorded. An optimal classifier to identify these positive cases was selected using an automated hyperparameter optimisation. The optimised model achieved an ROC AUC of 0.695 ± 0.045. The data collection window for determining each participant's vital sign baseline was increased from 4 to 8 or 12 weeks with no significant difference in model performance (F(2) = 0.80, p = 0.472). We demonstrate that 4 weeks of intermittently collected vital sign measurements could be used to predict SARS-CoV-2 PCR positivity, with applicability to other diseases causing similar vital sign changes. This is the first example of an accessible, smartphone-based remote monitoring tool deployable in a public health setting to screen for potential infections.

Indexed as

COVID-19SARS-CoV-2Body TemperatureCOVID-19 TestingFeasibility StudiesHumansPolymerase Chain ReactionSmartphone

Identifiers

PMID37386099
PMCPMC10310739

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.